Selective treatment of endothelial somatostatin receptors

• US 20060089299A1
• Filed: 07/26/2005
• Published: 04/27/2006
• Est. Priority Date: 09/01/1998
• Status: Abandoned Application

• Current Assignee: Alison Buchan, Julia G. Levy, Philippe Maria Clotaire Margaron, York Hsiang
• Original Assignee: Alison Buchan, Julia G. Levy, Philippe Maria Clotaire Margaron, York Hsiang
• Inventors: Levy, Julia G., Buchan, Alison, Margaron, Philippe Maria Clotaire, Hsiang, York
• Application Number:
  US11/189,597
• Publication Number:
  US 20060089299A1
• Time in Patent Office: Days
• US Class Current: 514/11.100
• CPC Class Codes: A61K 38/31 Somatostatins
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/02 of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention provides for the use of somatostatin receptor selective ligands (selective for SSTR1 or SSTR4) to treat human endothelial cells and to formulate medicaments for human use. The medicaments may for example be used to treat an angiogenic disease. In various embodiments, the angiogenic disease may for example be macular degeneration or a solid tumor. The SSTR1 or SSTR4 selective agonists may include the SSTR1 agonist (des-AA^1,2,5[DTrp⁸,IAamp⁹]SS).

Claims

1. A method for inhibiting angiogenesis in a human patient in need of such inhibition, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR1.

11. The method of claim 1 wherein the somatostatin receptor ligand is SS14 or des-AA^1,2,5 [DTrp⁸,IAamp⁹]SS.

19. The method of claim 1, wherein the patient is suffering from a disease selected from the group consisting of:

neovascularization of the choroid and retina, iris and cornea, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, rubeosis, hypoxia, angiogenesis in the eye associated with infection, angiogenic aspects of skin diseases, psoriasis, hemagiomas, capillary proliferation within atherosclerotic plaques, Osler-Webber Syndrome, myocardial angiogenesis, atherosclerotic plaque neovascularization, telangiectasia, hemophiliac joints'"'"', angiofibroma, wound granulation, intestinal adhesions, Crohn'"'"'s disease, scleroderma, hypertrophic scars, keloids, cat scratch disease and ulcers.

20. The method of claim 1, wherein the somatostatin receptor ligand is des-AA^1,2,5 [DTrp⁸,IAamp⁹]SS.

2. A method for inhibiting angiogenesis in a human patient in need of such inhibition, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR4.

12. The method of claim 2 wherein the somatostatin receptor ligand is SS14.

3. A method for treating age-related macular degeneration in a human patient in need of such treatment, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR1.

7. The method of claim 3 wherein the somatostatin receptor ligand is administered after the patient has undergone photodynamic therapy.

13. The method of claim 3 wherein the somatostatin receptor ligand is SS 14 or des-AA^1,2,5 [DTrp⁸,IAamp⁹]SS.

4. A method for treating age-related macular degeneration in a human patient in need of such treatment, comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR4.

8. The method of claim 4 wherein the somatostatin receptor ligand is administered after the patient has undergone photodynamic therapy.

14. The method of claim 4 wherein the somatostatin receptor ligand is SS14.

5. A method for inhibiting the angiogenic activity of human endothelial cells in a patient in need of such inhibition comprising administering to said patient an effective amount of a somatostatin receptor agonist ligand that binds SSTR1.

15. The method of claim 5 wherein the somatostatin receptor ligand is SS14 or des-AA^1,2,5 [DTrp⁸,IAamp⁹]SS.

6. A method for inhibiting the angiogenic activity of human endothelial cells in a patient in need of such inhibition comprising administering to said patient an effective amount of a somatostatin receptor ligand that binds with greater affinity to SSTR4 than to any other somatostatin receptor.

16. The method of claim 6 wherein the somatostatin receptor ligand is SS14.

9. A method for treating cancer by inhibiting solid tumour angiogenesis which comprises administering to a human patient in need of such treatment an effective amount of a somatostatin receptor ligand that binds SSTR1.

17. The method of claim 9 wherein the somatostatin receptor ligand is SS14 or des-AA^1,2,5 [DTrp⁸,IAamp⁹]SS.

10. A method for treating cancer by inhibiting solid tumour angiogenesis which comprises administering to a human patient in need of such treatment an effective amount of a somatostatin receptor ligand that binds SSTR4.

18. The method of claim 10 wherein the somatostatin receptor ligand is SS14.